(1) Company Name: FerroptoCure Inc.
(2) CEO: Yuji Otsuki
(3) Location:
Head Office:Fujimi Duplex B's 4F, 1-3-11 Fujimi, Chiyoda-ku, Tokyo
Research Laboratory:Nano Medical Innovation Center (iCONM),
3-25-14 Tonomachi, Kawasaki-ku, Kawasaki city, Kanagawa
FerroptoCure Australia Pty Ltd:Level 23, 68 Pitt Street, Sydney NSW 2000,
AustraliaModoras Accounting (SYD) Pty Ltd内）
(4) Established: May 2022
(5) Business Description: Drug discovery targeting ferroptosis
(6) Capital: JPY 10,000,000
(7)Company History
Keio University, Division of Gene Regulation Research (Establishment of the Saya Laboratory)
CD44vがxCTをがん細胞膜上で安定化を確認
CD44v陽性細胞で抗酸化物質の蓄積を確認
化学療法+スルファサラジンでのヒトPOC (縮小例およびPFS延長)
xCT阻害抵抗性獲得へのALDHの関与を確認
スルファサラジンとオキシフェドリンの合成致死を発見
Establishment of FerroptoCure, Inc.
Seed Round Financing of JPY 570 million
FC-001のPhase1治験 (AMEDシーズC)/FC-004の開発開始 (新規製剤特許を申請可能な開発)
Series A+Strengthening Program for Pharmaceutical Startup Ecosystem: 960 million
Establishment of an Australian Subsidiary